Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
5(50%)
Results Posted
75%(3 trials)

Phase Distribution

Ph phase_2
4
40%
Ph phase_3
3
30%
Ph early_phase_1
1
10%
Ph phase_1
2
20%

Phase Distribution

3

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
4(40.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(4)
Other(1)

Detailed Status

Completed4
Recruiting3
Active, not recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (10.0%)
Phase 12 (20.0%)
Phase 24 (40.0%)
Phase 33 (30.0%)

Trials by Status

completed440%
active_not_recruiting220%
recruiting330%
unknown110%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550
recruitingphase_2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

NCT07171606
recruitingphase_2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

NCT06353906
active_not_recruitingphase_3

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

NCT05201547
completedphase_1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05061550Phase 2

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Recruiting
NCT07171606Phase 2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

Recruiting
NCT06353906Phase 2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Recruiting
NCT05201547Phase 3

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Active Not Recruiting
NCT03307785Phase 1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Completed
NCT03737643Phase 3

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Active Not Recruiting
NCT05963334Phase 1

Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer

Completed
NCT01367002Phase 2

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Completed
NCT03940001Early Phase 1

A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer

Unknown
NCT00111007Phase 3

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10